- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01892241
Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
This study focused on the subsequential antiviral therapeutic strategies for chronic hepatitis B patients with spontaneous decline of HBV DNA after acute exacerbation. Patients fullfilled the following criterias were chosen for screening: They were antiviral treatment naı¨ve and had been positive for hepatitis B surface antigen (HBsAg) for at least 6 months, were positive for HBeAg and had an HBV DNA Level of more than 500,000IU/ml. Their serum alanine aminotransferase level was greater than 2 but less than or equal to 30 times the upper limit of the normal range, their peak value of total bililubin ranged from 2mg/ml to 20mg/ml and the prothrombin time activity was greater than 60%.
ALL of these patients were hospitalized and pretreated with anti-inflammation and liver protection agents such as Stronger Neo-Minophagen C, Polyunsaturated phosphatidylcholine (Essentiale), Ursodeoxycholic Acid and L-Glutathione reduced, without any nuclutide of nucleoside. Their ALT、TBIL and PTA were monitor weekly and HBVDNA level were measured every two weeks. Patients were eligible if their HBVDNA declined spontaneously by 2 log(10) IU/mL while their ALT falled below 10 ULN and TBIL falled below 2mg/ml within 8 weeks of pretreatment.
Patients with advanced fibrosis, cirrhosis and hepatoma were excluded. Other cause of chronic liver disease should be systematically checked to exclude co-infection with HDV, HCV and HIV, comorbidities with alcoholism, autoimmune and metabolic liver disease. Serious medical or psychiatric illnesses that had usage of corticosteroid or immunosup-pressive agents at the time of study were excluded. All patients in this study lived in Guangdong, a province of 100,000,000 populations, with same demographics. Owing to patients fear or refusal of liver biopsy, no patients had the liver biopsy and the rest relied on other clinical methods to obtain equivalent information of patient conditions. In our cases, ultrasonorgraphy helped to filter out patients with advanced fibrosis.The liver sonar examination was performed by two experi-enced hepatologists at least three times on each patient.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: 180µg of peginterferon alfa-2a
Cases in group A receive 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
|
180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
Altri nomi:
|
Comparatore attivo: Entecavir
cases in group B received an continual entecavir therapy(0.5
mg orally once daily)
|
continual entecavir therapy(0.5
mg orally once daily)
|
Nessun intervento: Control group
Those in group C didn't accept any antiviral regiment .
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Complete viralogic response
Lasso di tempo: week 96
|
Complete viralogic response was defined as suppression of HBV DNA to the level below 60IU/mL(detected by Cobas Amplicor HBV Monitor Test, Roche Diagnostics).
|
week 96
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
HBsAg loss and seroconversion
Lasso di tempo: week 24,48,72 and 96
|
HBsAg loss was defined as HBsAg titre less than 0.05 IU/mL and the HBsAg seroconversion was defined as the loss of HBsAg and the presence of anti-HBs antibody.
HBeAg seroconversion was defined as disappearance of HBeAg and appearance of anti-HBe antibody, while HBeAg loss was defined as disappearance of HBeAg only.
|
week 24,48,72 and 96
|
ALT normalization
Lasso di tempo: week 24,48,72 and 96
|
ALT normalization was defined as ALT level less than 40 IU/L(determined by a sequential multiple autoanalyzer).
|
week 24,48,72 and 96
|
Sick leave in patients in different groups
Lasso di tempo: week 48,72 and 96
|
week 48,72 and 96
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Gao Zhiliang, Doctor, The Third Affliated Hospital of Sun Yat-sen University
- Direttore dello studio: Zhao Zhixin, Doctor, The Third Affliated Hospital of Sun Yat-sen University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie del fegato
- Epatite, virale, umana
- Infezioni da Hepadnaviridae
- Infezioni da virus del DNA
- Infezioni da enterovirus
- Infezioni da Picornaviridae
- Epatite B
- Epatite
- Epatite A
- Epatite B, cronica
- Epatite cronica
- Agenti antinfettivi
- Agenti antivirali
- Peginterferone alfa-2a
- Entecavir
Altri numeri di identificazione dello studio
- ATFSHBVD
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Pegasys(Roche)
-
The Catholic University of KoreaUlsan University Hospital; Yonsei University; Kyungpook National University Hospital e altri collaboratoriCompletatoRisposta virologica sostenuta | IL28B PolimorfismoCorea, Repubblica di
-
National Institute of Diabetes and Digestive and...National Cancer Institute (NCI); National Institute of Allergy and Infectious... e altri collaboratoriCompletatoFibrosi, fegato | Cirrosi, Fegato | Cirrosi epatica | Epatite cronica cStati Uniti
-
University Hospital, GrenobleCompletato
-
Beijing Ditan HospitalCompletato
-
National Taiwan University HospitalNational Science Council, Taiwan; Department of Health, Executive Yuan, R.O.C...Terminato
-
Instituto Nacional de Cancerologia de MexicoReclutamentoMutazione del gene ALK | Carcinoma polmonare non a piccole cellule stadio IIIBMessico
-
Royal College of Surgeons, IrelandReclutamentoCarcinoma polmonare non a piccole celluleIrlanda
-
University of WashingtonNational Center for Advancing Translational Sciences (NCATS)Iscrizione su invito
-
Erasme University HospitalRoche Diagnostics; LHUB-ULBTerminatoInfezione da RSV | Infezioni virali influenzaliBelgio
-
Queen's UniversityCompletato